128 related articles for article (PubMed ID: 33014022)
1. Variation rs2235503 C > A Within the Promoter of
Silvestri R; Pucci P; De Santi C; Dell'Anno I; Miglietta S; Corrado A; Nicolí V; Marolda D; Cipollini M; Pellegrino E; Evangelista M; Bonotti A; Foddis R; Cristaudo A; Landi S; Gemignani F
Front Genet; 2020; 11():975. PubMed ID: 33014022
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
[TBL] [Abstract][Full Text] [Related]
3. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.
Garritano S; De Santi C; Silvestri R; Melaiu O; Cipollini M; Barone E; Lucchi M; Barale R; Mutti L; Gemignani F; Bonotti A; Foddis R; Cristaudo A; Landi S
J Thorac Oncol; 2014 Nov; 9(11):1662-8. PubMed ID: 25436799
[TBL] [Abstract][Full Text] [Related]
4. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A
Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018
[TBL] [Abstract][Full Text] [Related]
6. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany.
Rihs HP; Casjens S; Raiko I; Kollmeier J; Lehnert M; Nöfer K; May-Taube K; Kaiser N; Taeger D; Behrens T; Brüning T; Johnen G;
Biology (Basel); 2022 Dec; 11(12):. PubMed ID: 36552335
[TBL] [Abstract][Full Text] [Related]
8. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
13. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
14. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.
Sapede C; Gauvrit A; Barbieux I; Padieu M; Cellerin L; Sagan C; Scherpereel A; Dabouis G; Grégoire M
Cancer Sci; 2008 Mar; 99(3):590-4. PubMed ID: 18167128
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Landi D; Gemignani F; Landi S
Occup Environ Med; 2010 Apr; 67(4):233-6. PubMed ID: 19858537
[TBL] [Abstract][Full Text] [Related]
17. Soluble mesothelin-related protein in malignant pleural mesothelioma.
Azim HA; Gaafar R; Abdel Salam I; El-Guindy S; Elattar I; Ashmawy A; Khorshid O
J Egypt Natl Canc Inst; 2008 Sep; 20(3):224-9. PubMed ID: 20424652
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.
Yu M; Zhang Y; Jiang Z; Chen J; Liu L; Lou J; Zhang X
Environ Health Prev Med; 2015 Sep; 20(5):369-78. PubMed ID: 26188910
[TBL] [Abstract][Full Text] [Related]
19. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
